Kornimate/medical-research-clean huggingface dataset:
anthropometric and body composition measurements related to osteoporosis in geriatric population

Conditions: Osteoporosis Senile; Obesity, Visceral

Summary: the patients who consulted to the geriatric outpatient clinic between 2018 and 2019 were included in the study. the inclusion criterions were being at or over the age of 65 and diagnosed with osteoporosis according to who criteria. exclusion criteria include vertebral fracture due to known accidental traumas, history of drug therapy in the past year (biphosphonate, estrogen replacement therapy, glucocorticoids ), history of co-morbidities as malignancy, radiotherapy or chemotherapy, renal failure, hyperthyroidism, primer hyperparathyroidism, rheumatic disease or adrenal diseases. initially, a demographic form including age, sex, comorbidities, weight, height was filled by the participants. body mass index (bmi, ratio of height and weight, expressed as kg/m2) calculated. patients waist and hip circumference was measured (cm). fat percentage and skeletal muscle mass (smm) was calculated by using bioimpedance analysis (bia) (tanita tbf 300; tanita corp., tokyo, japan). skeletal muscle index (smi) was calculated from bia-based skeletal muscle mass with a formula as smm/height \[m2\] \[8\]. absi is measured as waist circumference (m) / (bmi(kg)2/3x height(m)5/6) \[4\]. osteoporosis was evaluated by using dual energy x-ray absorptiometry (dxa). according to the t-scores calculated from femur neck (fn) and lumbar spine (ls), subjects divided into 3 groups as following: a) normal: t-score is greater than -1 sd, b) osteopenia: t-score is between -1 and -2.5 sd, c) osteoporosis: t-score is lower than -2.5 sd. physical activity levels of patients were evaluated with the rapid assessment of physical activity (rapa) aerobic assessment \[9\]. patients divided into 5 groups as following: 1 = sedentary, 2 = underactive, 3 = regular underactive (light activities), 4 = regular underactive, and 5 = regular active). the study protocol was approved by the ethics committee (2018/0478) and all participants gave written informed consent.


Eligibility criteria:
inclusion criteria: * being at or over the age of 65 * diagnosed with osteoporosis according to who criteria exclusion criteria: * vertebral fracture due to known accidental traumas * history of drug therapy in the past year (biphosphonate, estrogen replacement therapy, glucocorticoids ) * history of co-morbidities as malignancy, radiotherapy or chemotherapy, renal failure, hyperthyroidism, primer hyperparathyroidism, rheumatic disease or adrenal diseases

Keywords: osteoporosis anthropometrics body composition
a study of mrna-1083 (sars-cov-2 and influenza) vaccine in healthy adult participants, ≥50 years of age

Conditions: SARS-CoV-2; Influenza

Summary: the purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mrna-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (sars cov 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (cohort a) and healthy adults 50 to \<65 years of age (cohort b).


Eligibility criteria:
key inclusion criteria: * healthy adults either ≥65 years of age (cohort a) or 50 to \<65 years of age (cohort b) at the time of consent (screening visit). * for female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to day 1, and agreement to continue adequate contraception through 3 months following vaccine administration. * fully vaccinated for covid-19 primary series according to the locally authorized or approved regimen, and their last covid-19 vaccine (primary series or booster) was ≥90 days prior to day 1. exclusion criteria: * participant is acutely ill or febrile (temperature ≥38.0 degrees celsius \[°c\]/100.4 degrees fahrenheit \[°f\]) 72 hours prior to or at the screening visit or day 1. * any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results. * participant has received systemic immunosuppressants for \>14 days in total within 180 days prior to day 1 (for corticosteroids, ≥10 milligrams \[mg\]/day of prednisone or equivalent) or is anticipating the need for systemic immunosuppressive treatment at any time during participation in the study. inhaled nasal and topical steroids are allowed. * received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days prior to study injections or plans to receive a vaccine authorized or approved by a local health agency within 28 days after the study injections. * received a seasonal influenza vaccine ≤150 days prior to day 1. * tested positive for influenza by local health authority-approved testing methods ≤150 days prior to day 1. * has had close contact to someone with covid-19 as defined by the centers for disease control and prevention (cdc) in the past 10 days prior to day 1. * has donated ≥450 milliliters (ml) of blood products within 28 days prior to the screening visit or plans to donate blood products during the study. note: other protocol-defined inclusion/exclusion criteria may apply.

Keywords: mrna-1083 mrna-1083 vaccine sars-cov-2 sars-cov-2 vaccine coronavirus virus diseases messenger rna influenza vaccine moderna
rdea3170 and febuxostat combination study in gout subjects

Conditions: Gout

Summary: this is a phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (pd) effects and safety of rdea3170 administered in combination with febuxostat compared to febuxostat administered alone in adult subjects with gout.


Eligibility criteria:
inclusion criteria: * able to understand the study procedures and the risks involved and is willing to provide written informed consent before the first study-related activity. * meets one or more criteria for the diagnosis of gout as per the american rheumatism association criteria for the classification of acute arthritis of primary gout. * body weight ≥ 50 kg (110 lbs) and a body mass index ≥ 18 and ≤ 45 kg/m2. * screening serum urate level ≥ 8 mg/dl. * free of any clinically significant disease or medical condition, per the investigator's judgment. exclusion criteria: * unable to take colchicine for gout flare prophylaxis. * history or suspicion of kidney stones. * any gastrointestinal disorder that affects motility and/or absorption. * unstable angina, new york heart association class iii or iv heart failure, ischemic heart disease, stroke, or deep venous thrombosis within 12 months prior to day 1; or subject is currently receiving anticoagulants. * screening laboratory parameters that are outside the normal limits and are considered clinically significant by the investigator. * estimated creatinine clearance \< 60 ml/min calculated by the cockcroft-gault formula using ideal body weight during the screening period. * taking losartan, fenofibrate, guaifenesin, or sodium-glucose linked transporter-2 inhibitors; chronic and stable doses are permitted if doses are stable for at least 14 days prior to study medication dosing. * unable or unwilling to comply with the study requirements or has a situation or condition that, in the opinion of the investigator, may interfere with participation in the study.
functional treatment planning utilizing 18-fdgal pet/ct in sbrt for liver metastases

Conditions: Liver Metastases

Summary: background: anatomical (traditional) stereotactic body radio therapy(sbrt) treatment planning assumes homogenous distribution of function in the normal liver tissue. in functional treatment planning, additional information on distribution of the function derived from functional imaging of normal tissue is taken into account. by functional treatment planning it becomes possible to prioritize and spare the best functioning part of an organ. aim: to test whether functional treatment planning based on 18-fdgal pet/ct may spare the best functioning liver tissue. endpoints: reduction in hepatic systemic clearance (k) in the dynamic 18-fdgal pet/ct scan one month after sbrt compared to the baseline status in sub-volumes recieving 15 gy or higher. secondly, the investigators will evaluate the toxicity to sbrt by a toxicity scoring system that includes biochemical measures as well as symptomatic scores.


Eligibility criteria:
inclusion criteria: * performance status \>2 * liver metastases refereed for sbrt exclusion criteria: * pregnancy * claustrophobia

Keywords: liver function galactose 18-f-deoxy-galactose
combined co2 fractional laser with bimatoprost 0.03% treatment of alopecia areata

Conditions: Alopecia Areata

Summary: the goal of this study is to evaluate the efficacy and safety of combined co2 fractional laser with bimatoprost 0.03% as novel treatment of alopecia areata. the main question to study is will the bimatoprost facilitate hair growth if added to fractional co2 laser treatment in alopecia areata.

the study included 30 patients who were diagnosed clinically and dermoscopically as alopecia areata with age ranged between 16-55 years. the patients are divided into 2 groups: group i, received fractional laser sessions with immediate and daily bimatoprost application and group ii, received only frequent laser sessions. laser sessions were given to each patch once every 3 weeks, the procedure was repeated for 3 times.

Eligibility criteria:
inclusion criteria: * patients with alopecia areata of the scalp (multilocuolaris or single patch). * patient aged from 16- 55 years old in both sex. * other treatment wash out period is two months. exclusion criteria: * ophiasis pattern and other patterns of alopecia areata. * chronic diseases of liver, heart, kidney and blood * pregnant women * infections of skin in site of intervention

Keywords: alopecia areata bimatoprost co2 fractional laser
effect of decreased pump prime volume on blood transfusions and postoperative complications of patients undergoing high risk cardiac surgical procedures

Conditions: Cardiac Surgery

Summary: the objective of this study is to evaluate the impact of reduced pump prime on blood transfusions and postoperative complications in patients at high risk of severe hemodilution during cpb. hypothesis the use of a new cpb circuit with a smaller internal volume, together with retrograde autologous priming of the lines (rap) will allow a smaller prime volume and therefore less significant hemodilution on pump. experimental design overview patients will be randomized on the morning of surgery to one of the two study groups in a 1:1 allocation scheme: 1. low pump prime 2. standard pump prime outcomes the primary outcome is the number of units of blood products transfused within the first 24 hours post cpb.


Eligibility criteria:
inclusion criteria: * \>18 y of age * non-emergent complex cardiac surgery (any procedure other than primary isolated cabg) * any of the following: hb \< 120 g/l (females) or \< 130 g/l (males)bsa \< 1.6 m2creatinine clearance \< 60 ml/min (cockcroft gault equation) exclusion criteria: * aptt \>50 s, inr\>1.5 * plt \< 100,000 x 106 * preoperative hemodialysis * tight aortic stenosis (aortic valve area \< 1 cm2) * tight lesion of the left main coronary artery (\> 60%) * use of aprotinin requested by the surgical team

Keywords: cardiac surgery pump prime blood transfusions
postoperative pain and incidence of extrusion following the use of two intra-canal medications in retreatment of single rooted teeth

Conditions: Endodontic Disease

Summary: this study aims to compare the postoperative pain and incidence of extrusion of two intracanal medications in the retreatment of single-rooted teeth. the main question it aims to answer is: does the injection of intra-canal medication into the shaped root canal after complete removal of the old obturating material lead to post-operative pain and paste extrusion to periapical tissues or not?


Eligibility criteria:
inclusion criteria: * patients with failed endodontic treatment in single root teeth * systemic free exclusion criteria: * muktirooted teeth
safety and efficacy of intravenous oav101 (avxs-101) in pediatric patients with spinal muscular atrophy (sma)

Conditions: Spinal Muscular Atrophy

Summary: to evaluate the safety, tolerability and efficacy of intravenous administration of oav101 (avxs-101) in patients with spinal muscular atrophy (sma) with bi-allelic mutations in the survival motor neuron 1 (smn1) gene weighing ≥ 8.5 kg and ≤ 21 kg, over a 12 month period.

this was an open-label, single arm, multi-center study designed to evaluate the safety, tolerability and efficacy of oav101 in participants with sma who weigh ≥ 8.5 kg and ≤ 21 kg. the study aimed to enroll approximately 24 to 30 participants, with approximately 6 to 10 participants across each of 3 weight brackets (8.5 to 13 kg, \>13 to 17 kg, \>17 to 21 kg). eligible participants received a single administration of oav101 at the approved dose of 1.1e14 vg/kg on day 1 (treatment period), and were followed for a period of 12 months. participants were admitted to the hospital on day -1 for pre-treatment baseline procedures. after receiving oav101 on day 1, participants underwent in-patient safety monitoring over the next 48 hours, after which the participant could be discharged, based on investigator judgment. after study completion, eligible participants could enroll into a long term follow-up study to collect additional safety and efficacy data. (coav101a12308 (nct05335876) https://classic.clinicaltrials.gov/ct2/show/nct05335876?term=coav101a12308\&draw=2\&rank=1))

Eligibility criteria:
inclusion * symptomatic sma diagnosis based on gene mutation analysis with bi-allelic survival motor neuron 1 (smn1) mutations (deletion or point mutations) and any copy of the survival motor neuron 2 (smn2) gene. * weight ≥ 8.5 kg and ≤ 21 kg at the time of screening visit 2 * naive to treatment or have discontinued an approved drug/therapy exclusion: * previous oav101 use or previous use of any adeno-associated virus serotype 9 (aav9) gene therapy * bmi \< 3rd percentile * participant with history of aspiration pneumonia or signs of aspiration * elevated anti-aav9 antibody * history of gene therapy, hematopoietic transplantation, or solid organ transplantation * inability to take corticosteroids * concomitant use of immunosuppressive therapy * requiring invasive ventilation, tracheostomy or awake non-invasive ventilation 9. administration of vaccines 2 weeks prior to infusion of oav101 * awake hypoxemia or awake oxygen saturation level decrease * hepatic dysfunction * presence of a confirmed or suspected infection * if previously treated with disease modifying therapy, specified washout times apply * documented any parental consanguinity.

Keywords: zolgensma oav101 avxs 101 gene therapy muscle atrophy sbma spinal and bulbar muscular atrophy spinal muscular atrophy bulbar muscular atrophy muscle function myopathy muscle wasting atrophied muscle loss of muscle strength
evaluation of a new self-assessed, home-based symptom score in cat allergic patients

Conditions: Cat Allergy

Summary: in the last decades the prevalence of allergies has reached epidemic proportions. 10 to 15% of the population suffers from cat allergy. investigators perform this study in order to further investigate symptom records and their evaluation in cat allergic patients. investigators primarily aim to better standardize the symptom recording of cat allergic persons under real-life conditions and to evaluate the effect of hypoallergenic cats on symptom strength.


Eligibility criteria:
inclusion criteria: * participant understands the nature, meaning and scope of the study. * signed informed consent after being informed. * male and female patients 18 years to 65 years of age. * positive screening prick test (mean wheal diameter equal or greater 3 mm) when tested with already standardized cat allergen extract. * positive screening prick test (wheal diameter equal or greater 3mm) to histamine dihydrochloride 10 mg/ml. * positive scratch test when tested with cat dander sample of participant's cat. * baseline symptoms with a severity of "1" in at least 2 different symptoms. * owner of a cat that lives in the same household. * cat will not have been washed in the 4 weeks before starting the test phase. exclusion criteria: * impaired in understanding the nature, meaning and scope of the study or incapable of giving written informed consent * participation in another study with investigational drug within the 30 days preceding and during the present study * women who are pregnant or breast feeding * intention to become pregnant during the course of the study * positive skin reaction in the prick test to negative control * history of anaphylactic reaction to pet allergens * severe diseases influencing the results of the present study by discretion of the investigator * immunotherapy with fel d 1 / cat allergen preparation during the past two years * skin lesions and excessive hair-growth in the skin test areas * treatment with prohibited concomitant medications according to section 8.3 with the exception of medications with local effects which will not influence the results of the skin tests and the results of the other tests (testing period). * the patient should not suffer from other respiratory allergies during this study

Keywords: symptom recording
tracking peripheral immune cell infiltration of the brain in central inflammatory disorders using [zr-89]oxinate-4-labeled leukocytes.

Conditions: Fibromyalgia; Chronic Fatigue Syndrome; Multiple Sclerosis; Healthy

Summary: this study will use brain positron emission tomography/ magnetic resonance imaging (pet/mri) and an investigational radioactive drug called \[zr-89\]oxine to track the location of white blood cells (also called leukocytes) in the body. pet/mri will be used to visualize labeled white blood cells and determine if they enter the central nervous system in conditions associated with brain inflammation (also called neuroinflammation). by better understanding the role of neuroinflammation in fibromyalgia, chronic fatigue syndrome, and multiple sclerosis, the investigator hopes to be able to better diagnose and treat patients in the future.


Eligibility criteria:
inclusion criteria: 1.18 to 65 years of age 2.healthy volunteer or * clinical diagnosis of multiple sclerosis (ms) or * meets 2016 american college of rheumatology (acr) case definition criteria for fibromyalgia or * meets 1994 fukuda case definition criteria for chronic fatigue syndrome exclusion criteria: 1. contraindication to mri 2. pregnancy 3. lactation 4. individuals who are unable to participate in the imaging portion due to severity of their medical condition 5. chronic infectious disease (e.g. hiv, hcv) 6. viral or bacterial illness requiring medical attention and/or antibiotics within 1 month of study participation 7. diagnosis of cancer, including leukemia 8. blood or blood clotting disorder 9. except for individuals with ms, a diagnosis of autoimmune disease is exclusionary 10. positive urine pregnancy test day of procedure or a serum pregnancy test within 48 hours prior to the administration of zirconium-89 oxinate-4-labeled leukocytes 11. currently enrolled in a clinical trial utilizing experimental therapies 12. contraindication to gadolinium based contrast agents
assessing microvascular resistance via imr to predict cumulative outcome in stemi patients undergoing primary pci

Conditions: Multi Vessel Coronary Artery Disease; STEMI

Summary: the purpose of this study is to assess whether the index of microcirculatory resistance (imr) can be considered a prognostic predictor for the occurrence of events at one year of follow up after primary percutaneous coronary intervention (pci) in st-elevation myocardial infarction (stemi) patients. any correlation between imr and the short and medium term outcomes, defined as cardiovascular death, re-myocardial infarct (mi), re-hospitalization for heart failure (hf), resuscitation or implantable cardioverter defibrillator (icd) appropriate shock, will be assessed in the study.

prospective, multicentre study designed to evaluate imr ability to predict events occurrence, defined as cardiovascular death, re-mi, re-hospitalization for hf, resuscitation or icd appropriate shock, during a 1 year follow-up period. all participants will have the culprit lesion treated following clinical practice and guidelines; fractional flow reserve (ffr) and imr will be measured after the primary pci procedure to evaluate treatment success and myocardial viability. non-culprit lesions will be functionally evaluated through ffr index and will be treated if ffr will show functional stenosis. ffr and imr will be measured to evaluate treatment success and myocardial viability. patients will be followed-up at 1m, 6m and 1y periods.

Eligibility criteria:
inclusion criteria: 1. patient of legal age in hosting country able and willing to provide informed consent form 2. hospital admission either within 12 h of symptom onset or between 12 and 24 h after onset with evidence of continuing ischemia 3. electrocardiographic st-segment elevation ≥1 mm in two or more contiguous ecg leads, or with a left bundle-branch block (lbbb) 4. multivessel diseased patients with lesions in the proximal 2/3 part of the vessels 5. culprit lesion eyeball (eb) identified during evaluation of basal angiography 6. presence of at least one non-culprit lesion \>50% eb detected in the basal angiography and eligible for pci for which the operators decision is to perform a staged pre-discharge angioplasty procedure exclusion criteria: 1. patients who cannot give informed consent 2. a life expectancy of less than 1 year 3. patients who are pregnant or nursing 4. contra-indication to angiography 5. allergy/intolerance to adenosine 6. contra-indication/allergy/intolerance to contrast media or to medical therapy foreseen for pci 7. documented allergy to adenosine diphosphate (adp) inhibitors (aspirin and clopidogrel) 8. new infarct on the same area of a previous infarct 9. critical non treatable lesion eb\>70% downstream of the culprit lesion 10. absence of non-culprit lesion/s 11. patient with hemodynamic instability not controllable with medical therapy and/or need intra aortic balloon pump implantation (iabp) 12. prior coronary artery bypass graft (cabg) or indication for cabg 13. patients with left main (lm) coronary artery disease requiring revascularization

Keywords: stemi imr ffr microcirculatory